Melbourne, Victoria, Australia.
+61 3 8559 6530
Subscribe
Email Us
Collaborate Now

Scientific Journals Articles March 2015

Expert Opinion on Biological Therapy

Drug Evaluation

Trametinib in the treatment of melanoma

Posted online on March 26, 2015. (doi:10.1517/14712598.2015.1026323)

Ramya Thota, Douglas B Johnson, and Jeffrey A Sosman

Vanderbilt University Medical Center, Department of Medicine,

777 PRB, 2220 Pierce Ave, Nashville, TN 37232

, USA +1 615 322 8131; +1 615 343 7602;

Read More: http://informahealthcare.com/doi/abs/10.1517/14712598.2015.1026323

_________________________________________________________________________________________

TUMOUR IMMUNOLOGY

A triple blow for cancer

Nature Reviews Immunology (2015)

Published online 27 March 2015
doi:10.1038/nri3844 

Int. J. Mol. Sci. 2015, 16(4), 6645-6667;

Article

Antitumor Effects of Vitamin D Analogs on Hamster and Mouse Melanoma Cell Lines in Relation to Melanin Pigmentation

Received: 13 January 2015 / Revised: 5 March 2015 / Accepted: 12 March 2015 / Published: 24 March 2015
doi:10.3390/ijms16046645

Case report

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
Michael Cecchini*, Mario Sznol and Stuart Seropian

  • Corresponding author: Michael Cecchini Michael.cecchini@yale.edu

Author Affiliations

Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA

For all author emails, please log on.

Journal for Immunotherapy of Cancer 2015, 3:10
doi:10.1186/s40425-015-0054-4

NON-CODING RNA

Editing suppresses melanoma progression
·         Sarah Seton-Rogers

Nature Reviews Cancer

15, 198 (2015)

Published online 24 March 2015
doi:10.1038/nrc3936

 

The Lancet Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Dr Jeffrey S Weber, MD, Sandra P D’Angelo, MD, David Minor, MD, F Stephen Hodi, MD, Ralf Gutzmer, MD, Bart Neyns, MD, Christoph Hoeller, MD, Nikhil I Khushalani, MD, Wilson H Miller Jr, MD, Christopher D Lao, MD, Gerald P Linette, MD, Luc Thomas, MD, Paul Lorigan, FRCP, Kenneth F Grossmann, MD, Jessica C Hassel, MD, Michele Maio, MD, Mario Sznol, MD, Paolo A Ascierto, MD, Peter Mohr, MD, Bartosz Chmielowski, MD, Alan Bryce, MD, Inge M Svane, MD, Jean-Jacques Grob, MD, Angela M Krackhardt, MD, Christine Horak, PhD,

Alexandre Lambert, PhD, Arvin S Yang, MD, James Larkin, FRCP

Published Online: 17 March 2015
DOI: http://dx.doi.org/10.1016/S1470-2045(15)70076-8

Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis

Stephan W Jahn, Karl Kashofer, Iris Halbwedl, Gerlinde Winter, Laila El-Shabrawi-Caelen, Thomas Mentzel, Gerald Hoefler and Bernadette Liegl-Atzwanger

Modern Pathology , (13 March 2015) | 
doi:10.1038/modpathol.2015.39

___________________________________________________________________________________________________________________________________

Drug addiction revealed in BRAF and MEK inhibitor-resistant melanoma cells

Nature Reviews Clinical Oncology (2015)
Published online 17 February 2015
doi:10.1038/nrclinonc.2015.28

___________________________________________________________________________________________

Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity

Y Yang1,7, C Gorzelanny1,7, A T Bauer1, N Halter1, D Komljenovic2, T Bäuerle3, L Borsig4, M Roblek4 and S W Schneider1

  1. 1Department of Dermatology, Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
  2. 2Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  3. 3Institute of Radiology, University Hospital Erlangen, Erlangen, Germany
  4. 4Institute of Physiology, University of Zürich and Zürich Center for Integrative Human Physiology, Zürich, Switzerland

Correspondence: Professor SW Schneider, Department of Dermatology, Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. E-mail: stefan.schneider@medma.uni-heidelberg.de

5These authors contributed equally to this work.

Received 27 March 2014; Revised 9 January 2015; Accepted 14 January 2015
Advance online publication 9 March 2015
Oncogene advance online publication 9 March 2015;
doi: 10.1038/onc.2015.40

_____________________________________________________________________________________________________________________________________

RESEARCH ARTICLES

 Sci. Signal., 10 March 2015

Phosphorylation of eIF2? triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma

  1. Jordan Wengrod1,
  2. Ding Wang1,
  3. Sarah Weiss1,
  4. Hua Zhong2,
  5. Iman Osman3,4, and
  6. Lawrence B. Gardner1,4,5,*

Vol. 8, Issue 367, p. ra27
DOI: 10.1126/scisignal.aaa0899

________________________________________________________________________________________

The Journal of the American Medical Association

Risk-Stratified Screening for Detection of Melanoma

Vernon K. Sondak, MD1; L. Frank Glass, MD1; Alan C. Geller, MPH, RN2

JAMA. 2015;313(6):616-617.
doi:10.1001/jama.2014.13813.

____________________________________________________________________________________________________

Paper

Infrared imaging of primary melanomas reveals hints of regional and distant metastases

  1. Waldaand  E. Goormaghtigh*a

Show Affiliations

Analyst, 2015,140, 2144-2155

Royal Society of Chemistry
Received 12 Oct 2014, Accepted 17 Dec 2014
First published online 17 Dec 2014 
DOI: 10.1039/C4AN01831A

__________________________________________________________________________________________________________________

mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation

William Damsky Goran Micevic Katrina Meeth Viswanathan Muthusamy David P. Curley Manjula Santhanakrishnan Ildiko Erdelyi James T. Platt Laura Huang Nicholas Theodosakis M. Raza Zaidi Scott Tighe Michael A. Davies David Dankort Martin McMahon Glenn Merlino Nabeel Bardeesy Marcus Bosenberg

Cancer Cell  Volume 27, Issue 1, p41–56, 12 January 2015
DOI: http://dx.doi.org/10.1016/j.ccell.2014.11.014

_______________________________________________________________________________________________________________

mTOR Signaling in Melanoma: Oncogene-Induced Pseudo-Senescence?

George P. Souroullas Norman E. Sharpless

Cancer Cell Volume 27, Issue 1, p3–5, 12 January 2015
DOI: http://dx.doi.org/10.1016/j.ccell.2014.12.005

 

Menu